Viewing Study NCT07336732


Ignite Creation Date: 2026-03-26 @ 3:17 PM
Ignite Modification Date: 2026-03-30 @ 12:07 AM
Study NCT ID: NCT07336732
Status: RECRUITING
Last Update Posted: 2026-03-20
First Post: 2025-12-18
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations
Sponsor: Avistone Biotechnology Co., Ltd.
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module